Why do neuroprotective drugs that are so promising in animals fail in the clinic? An industry perspective
- 3 October 2002
- journal article
- review article
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 29 (11), 1030-1034
- https://doi.org/10.1046/j.1440-1681.2002.03767.x
Abstract
1. No neuroprotective drug has yet been shown to be effective in treating acute ischaemic stroke in the clinic, despite evidence of efficacy in animal models. 2. An academic/industry round‐table group recently published guidelines to be met if a drug was to be progressed to clinical trial. 3. Major points included obtaining full dose–response evaluation and measurement of the therapeutic time window for efficacy, functional behavioural testing in addition to measurement of infarct volume, measurement of physiological parameters, use of appropriate models (transient and permanent focal ischaemia) and reproducibility of data by external laboratories. 4. The present paper examines both failed compounds and disodium 4‐[(tert‐butylimino) methyl] benzene‐1, 3‐disulphonate N‐oxide (NXY‐059), a nitrone radical‐trapping agent currently in clinical development. It aims to determine whether these guidelines were met by compounds that have failed and, thus, determine whether following the guidelines, as is being done with NXY‐059, will increase the chances of developing efficacious drugs for treating acute ischaemic stroke. 5. It is concluded that we will only achieve the goal of producing a clinically effective neuroprotective agent if the guidelines have been met by the novel compound under investigation.Keywords
This publication has 30 references indexed in Scilit:
- NXY-059, a Free Radical–Trapping Agent, Substantially Lessens the Functional Disability Resulting From Cerebral Ischemia in a Primate SpeciesStroke, 2001
- Recommendations for Standards Regarding Preclinical Neuroprotective and Restorative Drug DevelopmentStroke, 1999
- Clomethiazole Acute Stroke Study (CLASS)Stroke, 1999
- Delayed Treatment With an Adenosine Kinase Inhibitor, GP683, Attenuates Infarct Size in Rats With Temporary Middle Cerebral Artery OcclusionStroke, 1998
- Clinical Experience With Excitatory Amino Acid Antagonist DrugsStroke, 1995
- Tirilazad reduces cortical infarction after transient but not permanent focal cerebral ischemia in rats.Stroke, 1992
- Induced hypertension during restoration of flow after temporary middle cerebral artery occlusion in the rat: Effect on neuronal injury and edemaSurgical Neurology, 1991
- Animal models of stroke: are they relevant to human disease?Stroke, 1990
- Reversible middle cerebral artery occlusion without craniectomy in rats.Stroke, 1989
- Cerebral blood flow and edema following carotid occlusion in the gerbil.Stroke, 1980